Painful Diabetic Neuropathy: Treatment with Temporary Neuromodulation
Painful diabetic neuropathy (PDN) is chronic nerve pain caused by long-term diabetes, most often felt in the feet and lower legs. The NS100 by NeuroDynamics Global is an FDA-cleared 20-day temporary neuromodulation therapy that targets PDN pain without a permanent implant and without opioids.
What is painful diabetic neuropathy?
Painful diabetic neuropathy (PDN) is one of the most common complications of diabetes. Sustained high blood glucose damages the small nerves that supply sensation to the feet and legs, producing a chronic, often disabling pain that medications alone frequently fail to control.
Common symptoms include burning pain in the feet, electric-shock or shooting sensations, persistent tingling or numbness, sleep disruption, and difficulty walking. Symptoms typically begin in the toes and feet and progress upward over time.
PDN affects an estimated 20–30% of people with type 1 or type 2 diabetes who have had the disease for several years, and it is one of the leading reasons people with diabetes seek pain specialty care.
Key facts
- 20-day temporary therapy — no permanent implant left in the body
- FDA-cleared Class II medical device
- Non-opioid, non-pharmacologic treatment
- Covered by Medicare for eligible patients
- Placed during a minimally invasive in-office procedure
- Removed in a simple in-office visit on day 20
Why it matters
20-day protocol
A defined, time-limited course of therapy. Worn continuously for 20 days, then removed.
FDA-cleared
Class II medical device cleared for chronic pain associated with painful diabetic neuropathy.
Peripheral nerve target
Delivers gentle electrical stimulation directly to peripheral nerves to help modulate pain signals.
Provider supervised
Placed and removed by a trained physician in a minimally invasive in-office procedure.
How NS100 by NeuroDynamics Global treats PDN
NS100 is a peripheral nerve stimulation (PNS) therapy that delivers programmable electrical pulses to the nerves involved in PDN pain. The therapy is delivered for a defined 20-day window — long enough to drive a sustained neuromodulatory effect, short enough to avoid the long-term commitment of a permanent implant.
Because NS100 is temporary, there is no implanted pulse generator or permanent hardware to maintain, no battery to replace, and no surgery to remove a permanent device. At the end of the 20-day protocol the leads are removed in a simple in-office visit.
Many patients have reported meaningful pain relief that continues well after device removal. Individual results vary; eligibility, candidacy, and expected outcomes are determined by your treating provider.
How NS100 differs from other PDN treatments
Compared with permanent spinal cord stimulators (SCS), NS100 targets peripheral nerves directly and is removed after 20 days — there is no permanent implant. Compared with oral medications such as gabapentin, pregabalin, duloxetine, or opioids, NS100 is non-pharmacologic and avoids systemic side effects. Compared with topical agents and TENS, NS100 delivers therapy directly at the nerve target rather than through skin.
If you have not gotten adequate relief from first-line medications, or you want a non-opioid option that does not require a permanent implant, NS100 may be appropriate. Your provider will confirm candidacy.
Frequently asked questions
Ready to learn if NS100 is right for you?
Connect with our team. We'll help you understand candidacy, coverage, and next steps.